Mycobacterium fortuitum meningitis associated with an epidural catheter: Case report and a review of the literature

Pharmacotherapy

Volumn 19, Issue 5, 1999, Pages 661-666

  Madaras Kelly, Karl J ^a,c   DeMasters, Troy A ^a,c   Stevens, Dennis L ^b,c  

^a IDAHO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACLOFEN; BECLOMETASONE; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOCUSATE SODIUM; DOXYCYCLINE; ERYTHROMYCIN; FAMOTIDINE; FELODIPINE; HYDROMORPHONE; IMIPENEM; ISONIAZID; MINOCYCLINE; NORTRIPTYLINE; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; EPIDURAL CATHETER; EPIDURAL DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MENINGITIS; MYCOBACTERIUM FORTUITUM;

EID: 0032900381     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.8.661.31530     Document Type: Article

References (26)

1. Cegielski JP, Wallace RJ. Infections due to nontuberculous mycobacteria. In: Scheld WM, Whiteley RJ, Durack DT, eds. Infections of the central nervous system. Philadelphia: Lippincott-Raven, 1997:445-60
2. Wallace RJ, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985;152(3):500-13.
3. Wallace RJ, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983;5(4):657-79.
4. Dalvasio JR, Pankey GA, Wallace RJ, Jones DB. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 1981;1(5):1068-74.
5. Flor A, Capdevila JA, Martin N, Gavalda J, Pahissa A. Nontuberculous mycobacterial meningitis: report of two cases and review. Clin Infect Dis 1996;23:1266-73.
6. Dalsovisio JR, Pankey GA. Problems in diagnosis and therapy of Mycobacterium fortuitum infections. Am Rev Respir Dis 1978;117:625-30.
7. Hand WL, Sanford JP. Mycobacterium fortuitum - a human pathogen. Ann Intern Med 1970;73:971-7.
8. Santamaria-Jaquregui J, Sanz-Hospital J, Berenguer J, Munoz D, Gomez-Mampaso E, Bouza E. Meningitis caused by Mycobacterium fortuitum. Am Rev Respir Dis 1984;130:136-7.
9. Smith MB, Boyars MC, Woods GL. Fatal Mycobacterium fortuitum meningitis in a patient with AIDS. Clin Infect Dis 1996;23:1327-8.
10. Jacob CN, Henein SS, Heurich AE, Kamholz S. Nontuberculous mycobacterial infection of the central nervous system in patients with AIDS. South Med J 1993;86(6):638-40.
11. Chan KH, Mann KS, Seto WH. Infection of a shunt by Mycobacterium fortuitum: case report. Neurosurgery 1991;29:472-4.
12. Gilbert DN, Moellering RC, Sande MA, eds. Treatment of Mycobacterium infections. In: The Sanford guide to antimicrobial therapy, 27th ed. Vienna, VA: Antimicrobial Therapy Inc., 1997:78-83.
13. McEvoy GK, ed. Anti-inflammatory agents. AHFS 97 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997:2134-7.
14. Swenson JM, Thornsberry C, Silcox VA. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth dilution. Antimicrob Agents Chemother 1982;22(2):186-92.
15. Swenson JM, Wallace RJ, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacteria chelonae. Antimicrob Agents Chemother 1985;28(6):807-11.
16. Sanchez-Carillo C, Cotarelo M, Cercenado E, Vincente T, Blazquez R, Bouza E. Comparative in vitro activity of sparfloxacin and eight other antimicrobials. J Antimicrob Chemother 1996;37:151-4.
17. Wallace RJ, Brown BA, Onyi GO. Susceptibilities of Mycobacterium biovar fortuitum and two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991;35(4):773-5.
18. Brown BA, Wallace RJ Jr, Onyi GO, Rosas VD, Wallace RJ. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36(1):180-4.
19. Breidis DJ, Robson HG. Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother 1978;13: 1042-3.
20. Galvao P, Lomar A, Francisco W. Cefoxitin penetration in patients with purulent meningitis. Antimicrob Agents Chemother 1980;17:526-9.
21. Thea D, Barza M. Use of antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am 1989;3(3):553-67.
22. Ristuccia A, LeFroek J. Cerebrospinal fluid penetration of antimicrobials. Antibiot Chemother 1992;45:118-52.
23. Wolff M, Boutron L, Singlas E. Penetration of ciprofloxacin into the CSF of patients with bacterial meningitis. Antimicrob Agents Chemother 1987;31:899-902.
24. Sanche S, Williams K, Stein K. Cerebrospinal fluid penetration of clarithromycin and 14-hydroxyclarithromycin [abstr]. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17-20, 1993.
25. Modai J, Vittecoq D, Decazes D. Penetration of imipenem and cilastatin into the CSF of patients with bacterial meningitis. J Antimicrob Chemother 1985;16:751-5.
26. Yim CW, Flynn N, Fitzgerald F. Penetration of oral doxycycline into the CSF of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985;28:347-8.